Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

scmp.com - Aileen Chuang - China's Fosun Pharma eyes spin-off Hong Kong IPO of vaccine unit
China's Fosun Pharma eyes spin-off Hong Kong IPO of vaccine unit
South China Morning Post

The board of Shanghai Fosun Pharmaceutical approved the spin-off and Hong Kong listing of its vaccine unit, aiming to bolster the business as biotechnology shares continue to outperform in the city's stock market. The board cleared the proposed…

bloomberg.com - Europe's US Reality Check, Trump Sues Dimon For $5B, Big Pharma's Llama Secret
Europe's US Reality Check, Trump Sues Dimon For $5B, Big Pharma's Llama Secret
Bloomberg

Bloomberg Daybreak EU Podcast • Browse all episodes Your morning briefing, the business news you need in just 15 minutes. On today's podcast: (1) Europe is ready to get back to work with the US, wary, frustrated and knowing it can't trust an…

fortune.com - Nick Lichtenberg - Inside Big Pharma, VC's big bet on AI: 'We wouldn't fly in an airplane designed by hand, but all of our drugs are designed like that'
Inside Big Pharma, VC's big bet on AI: 'We wouldn't fly in an airplane designed by hand, but all of our drugs are designed like that'
Fortune

In the high-stakes world of modern medicine, finding a cure should be mathematically impossible. Researchers estimate there are 10^60 possible chemical compounds—or 10 to the 60th power, a number greater than the stars in the observable…

thehindu.com - The Hindu Bureau - Sun Pharma gets DCGI nod to make, market generic semaglutide injection in India for weight management
Sun Pharma gets DCGI nod to make, market generic semaglutide injection in India for weight management
The Hindu

Sun Pharmaceutical Industries Ltd said it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist…

thehindubusinessline.com - Sun Pharma gets regulatory approval for generic semaglutide in India
Sun Pharma gets regulatory approval for generic semaglutide in India
BusinessLine

Sun Pharmaceutical has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection, the company said, as it joins domestic drugmakers lining up to launch in India and…

marketbeat.com - Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital
MarketBeat

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its 'buy' rating reiterated by equities researchers at D. Boral Capital in a research note issued on Friday, Benzinga reports. They currently have a $33.00 target price on the stock. D.

lionessofjudah.substack.com - Lioness of Judah Ministry - SCANDAL: The PREP Act Gave Big Pharma Legal Immunity to Profit-No Matter the Harm
SCANDAL: The PREP Act Gave Big Pharma Legal Immunity to Profit-No Matter the Harm
Exposing The Darkness

Exposing The Darkness is a reader-supported publication. To support my work, please consider becoming a paid subscriber. One-time or recurring donations can be made through Ko-Fi: ⚡ What aren't they telling you? Please Join Exposing the…

deccanchronicle.com - Neeraj Kumar - Telangana Rising Policies Impress All, Says Sridhar Babu
Telangana Rising Policies Impress All, Says Sridhar Babu
Deccan Chronicle

Hyderabad: With a 60 per cent strike rate on projects from memoranda of understanding (MoUs) signed during 2024 and 2025 summits, surpassing the national average of 35 per cent, the Telangana government showcased the state's vibrant ecosystem for…

forbes.com - Trefis Team - Is The Fall In Abbott Stock Justified?
Is The Fall In Abbott Stock Justified?
Forbes

CANADA - 2025/10/12: In this photo illustration, the Abbott Laboratories logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Abbott…

cnbc.com - Annika Kim Constantino - What obesity drugmakers see next in the market: More pills, easier access and drug combinations
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
CNBC

Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC spoke to executives from Eli Lilly, Novo Nordisk…

upi.com - On This Day: Rock and Roll Hall of Fame inducts first class
On This Day: Rock and Roll Hall of Fame inducts first class
UPI

The Rock and Roll Hall of Fame and Museum is seen in Cleveland on October 17, 2006. File Photo by Kevin Dietsch/UPI Pedestrians wear protective respiratory masks in Beijing on January 23, 2020, the same day the government issued lockdown orders for…

theatlantic.com - Benjamin Mazer - America's Real 'Secretary of War'
America's Real 'Secretary of War'
The Atlantic

Three days into 2026, the United States military seized a foreign leader: Nicolás Maduro. Four days after that, the U.S. health department freed a longtime prisoner of war: saturated fats. At a recent press conference announcing the…

deccanchronicle.com - L. Venkat Ram Reddy - Congress Gets 10 Times More Deals At Davos Than BRS
Congress Gets 10 Times More Deals At Davos Than BRS
Deccan Chronicle

The scale of investments secured by the Congress government is nearly 10 times higher than what the previous BRS government managed during its decade-long tenure from 2014 to 2023. Data from the IT and industries department reveal that between 2018…

upi.com - UPI Almanac for Friday, Jan. 23, 2026
UPI Almanac for Friday, Jan. 23, 2026
UPI

The Rock and Roll Hall of Fame and Museum is seen in Cleveland on October 17, 2006. File Photo by Kevin Dietsch/UPI A Chinese soldier wears a protective mask in Beijing on January 23, 2020, the same day the government issued lockdown orders for the…

marketbeat.com - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Rating of 'Buy' from Analysts
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Rating of 'Buy' from Analysts
MarketBeat

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has earned a consensus rating of 'Buy' from the eleven analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating…

Receive a Daily briefing on Pharma Industry News

Get Started